Decentralized Solutions: Expanding Clinical Trial Access

By Leslie Carney, Senior Director, Patient Solutions, Elligo Health Research®

The clinical research landscape is increasingly adopting decentralized clinical trials (DCTs) and hybrid designs to enhance patient accessibility and inclusivity, addressing the limitations of traditional site-based models that often exclude diverse populations. This shift is exemplified by Elligo Health Research, which pioneers fully virtual and remote studies aimed at reducing participant burden through innovative strategies such as virtual screening visits, mobile healthcare services, and direct-to-patient drug delivery. By integrating both on-site and remote elements, hybrid trials make participation feasible for individuals in geographically isolated areas.

Collaboration with trusted community physicians who have established relationships with patients is vital for engaging historically underrepresented populations. This community-based recruitment strategy ensures that trials are tailored to meet the specific needs of diverse demographics, fostering inclusivity and diversity in clinical research. Looking forward, DCTs and hybrid trials not only address logistical barriers but also align with regulatory expectations, enhancing the validity and applicability of research findings. Elligo Health Research is committed to dismantling obstacles to participation and creating a clinical trial landscape that ultimately leads to more patient-centric research outcomes.